Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco

作者：Eleonora Gariazzo, Arielle Elkrief, Kyle Concannon, Daniele Ognissanti, Alessandra Dodi, Valentina Favorito, Alessandro Di Federico, Andrea De Giglio, Leonardo Brunetti, Valentina Santo, Federica Pecci, M Aldea, Edoardo Garbo, J. Alessi, Jaclyn LoPiccolo, Francesco Paoloni, Mizuki Nishino, Lynette M. Sholl, Narjust Florez, Julia Rotow, Stacey M. Frumm, Lingzhi Hong, Jianjun Zhang, Don Gibbons, X. Wang, Lorenza Landi, Laura Cipriani, Mehrdad Rakaee, Alessio Cortellini, Marcello Tiseo, Federico Cappuzzo, Andrea Ardizzoni, Mark M. Awad, John V. Heymach, Stefano Scalera, Marcello Maugeri‐Saccà, Giulio Metro, N. Vokes, Adam Schoenfeld, Biagio Ricciuti · 发表于：Clinical Cancer Research · 年份：2026 · DOI：10.1158/1078-0432.ccr-25-4793 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Research Studies、Inflammatory Biomarkers in Disease Prognosis

PURPOSE: Predictive biomarkers of response to immune checkpoint inhibitors (ICI) remain poorly defined in patients with non-small cell lung cancer (NSCLC) without a history of tobacco use and lacking actionable genomic alterations (AGA). We aimed to identify clinical and molecular predictors of response to ICI-based regimens in patients who have never smoked and lack AGAs. EXPERIMENTAL DESIGN: We retrospectively analyzed patients with metastatic, AGA-negative NSCLC who never smoke treated with ICI-based regimens across multiple independent cohorts. Tumor-infiltrating lymphocyte (TIL) densities were quantified using a machine learning-based algorithm, and immune cell biomarkers were assessed with multiplexed immunofluorescence. Transcriptomic correlates of ICI response were analyzed in the Stand Up To Cancer cohort. RESULTS: Among 741 patients with AGA-negative NSCLC and no history of tobacco use, the objective response rate (ORR) was 23.2%, median progression-free survival (mPFS) was 4.5 months, and median overall survival (mOS) was 16.8 months. PD-L1 ≥90% and tumor mutational burden (TMB) ≥90th percentile were independently and significantly associated with improved ORR, mPFS, and mOS (all P <0.01). PD-(L)1 + CTLA-4 combinations outperformed chemoimmunotherapy and PD-(L)1 monotherapy in terms of mPFS and mOS. Transcriptomic analysis revealed enrichment of innate and adaptive immune pathways in responders, including increased MHC class I/II antigen presentation and T-cell act...